Switching from ACE inhibitors, beta-blockers, calcium antagonists or diuretics to candesartan improves efficacy and tolerability

Blood Pressure

Volumn 11, Issue 5, 2002, Pages 310-319

  Porcellati, Carlo ^a   Omboni, Stefano ^a   Agozzino, A ^a   Amato, M ^a   Ambrosoli, S ^a   Ambrosio, G B ^a   Ambrosioni, E ^a   Baggioni, G ^a   Baldari, G ^a   Benetti, G ^a   Bevilacqua, M ^a   Bolondi, L ^a   Brunelli, C ^a   Campanini, M ^a   Capone, P ^a   Capponi, A ^a   Cappelletti, C ^a   Carrino, G ^a   Caruso, D ^a   Celegon, L ^a   Chiesa, F ^a   Coglitore, S ^a   Corinaldesi, R ^a   Cucchini, F ^a   De Angelis, A ^a   De Martino, U ^a   De Matteis, C ^a   De Micheli, E ^a   Del Vecchio, E ^a   Daniele, E ^a   Fenelli, M ^a   Forzoni, M ^a   Francesconi, A ^a   Franchini, A ^a   Fusaroli, M ^a   Gaio, M ^a   Giannandrea, A ^a   Giasi, M ^a   Giorgi, G ^a   Greco Lucchina, P ^a   Grimaldi, U ^a   Guariglia, A ^a   Guglielmi, M ^a   Lanzafame, A ^a   Laurini, G ^a   Locatelli, F ^a   Lombardo, D ^a   Lotti, G ^a   Maiorano, G ^a   more..

^a NONE   (Italy)

Author keywords

Adverse events; Adverse reactions; Antihypertensive treatment; Candesartan cilexetil; Hypertension

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; THIAZIDE DIURETIC AGENT;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; ASTHENIA; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DATA ANALYSIS; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ESSENTIAL HYPERTENSION; FEMALE; FLUSHING; HEADACHE; HEART PALPITATION; HUMAN; IMPOTENCE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE CRAMP; PERIPHERAL EDEMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SITTING; SYSTOLIC BLOOD PRESSURE; TREATMENT FAILURE; TREATMENT OUTCOME; VERTIGO;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BENZOTHIADIAZINES; BIPHENYL COMPOUNDS; CALCIUM CHANNEL BLOCKERS; DIURETICS; FEMALE; HUMANS; MALE; MIDDLE AGED; RETREATMENT; SODIUM CHLORIDE SYMPORTER INHIBITORS; TETRAZOLES;

EID: 18744361848     PISSN: 08037051     EISSN: None     Source Type: Journal    
DOI: 10.1080/080370502320779520     Document Type: Article

References (24)

1. Guidelines Subcommittee of the World Health Organization-International Society of Hypertension (WHO-ISH) Mild Hypertension Liaison Committee. 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens 1999; 17: 151-83.
2. Cohen J.S. Adverse drugs effects, compliance, and initial doses of antihypertensive drugs recommended by the Joint National Committee vs the Physicians' Desk Reference. Arch Int Med 2001; 161: 880-5
3. Dusing R, Weisser B, Mengden T, Wetter H. Changes in antihypertensive therapy: the role of adverse events and compliance. Blood Press 1998; 7: 313-15
4. Sever P. Candesartan cilexetil: a new, long-acting, effective angiotensin II type 1 receptor blocker. J Human Hypertens 1997; 11 Suppl 2: S291-5.
5. McClellan KJ, Goa KL. Candesartan cilexetil. A review of its use in essential hypertension. Drugs 1998; 56: 847-69.
6. McInnes GT, O'Kane KP, Jonker J, Roth J. The efficacy and tolerability of candesartan cilexetil in an elderly hypertensive population. J Human Hypertens 1997; 11 Suppl 2: S75-80.
7. Sever PS. Key feature of candesartan cilexetil and a comparison with other angiotensin II receptor antagonists. J Human Hypertens 1999; 13 Suppl 1: S3-10.
8. Zanchetti A, Omboni S. Comparison of candesartan versus enalapril in essential hypertension. Italian Candesartan Study Group. Am J Hypertens 2001; 14: 129-34.
9. Kloner RA, Weinberger M, Pool JL, Chrysant SG, Prasad R, Harris SM, Zyczynski TM, Leidy NK, Michelson EL. CASTLE Study Investigators. Comparative effects of candesartan cilexetil and amlodipine in patients with mild systemic hypertension. Comparison of candesartan and amlodipine for safety, tolerability and efficacy (CASTLE) Study Investigators. Am J Cardiol 2001; 87: 727-31.
10. Andersson OK, Neldman S. The antihypertensive effect and tolerability of candesartan cilexetil, a new generation angiotensin II antagonist, in comparison with losartan. Blood Press 1998; 7: 53-9.
11. Baumgart P, Reismann J, Pohlmeyer H, Dusing R. Change from ACE-inhibitor, Ca-antagonist or beta-blocker to candesartan cilexetil: better efficacy and tolerance. SWITCH study (German study segment). Dtsch Med Wochenschr 2001; 126: 547-50.
12. Ruzicka M, Leenen FH. Monotherapy versus combination therapy as first line treatment of uncomplicated arterial hypertension. Drugs 2001; 61: 943-54
13. Kaplan N. Low dose combinations in the treatment of hypertension: theory and practice. J Hum Hypertens 1999; 13: 707-10
14. Lewis MJ, Ross PJ, Henderson AH. Rebound effect after stopping beta-blockers. Br Med J 1979; 2: 606.
15. Benetos A, Rudnichi A, Safar M, Guize L. Pulse pressure and cardiovascular mortality in normotensive and hypertensive subjects. Hypertension 1998; 32: 560-4.
16. Millar JA, Lever AF, Burke V. Pulse pressure as a risk factor for cardiovascular events in the MRC Mild Hypertension Trial. J Hypertens 1999; 17: 1065-72.
17. Asmar R, Lacourciere Y. A new approach to assessing antihypertensive therapy: effect of treatment on pulse pressure. Candesartan cilexetil in Hypertension Ambulatory Measurement of Blood Pressure (CHAMP) Study Investigators. J Hypertens 2000; 18: 1683-90.
18. Burt VL, Cutler JA, Higgins M, et al. Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population. Data from the health examination surveys, 1960 to 1991. Hypertension 1995; 26: 60-9.
19. Mancia G, Sega R, Milesi C, Cesana G, Zanchetti A. Bloodpressure control in the hypertensive population. Lancet 1997; 349: 454-7.
20. Moan A, Risanger T, Eide I, Kjeldsen SE. The effect of angiotensin II receptor blockade on insulin sensitivity and sympathetic nervous system activity in primary hypertension. Blood Press 1994; 3: 185-8.
21. Ashino K, Gotoh E, Sumita S, et al. Effect of an angiotensin receptor antagonist, TCV-116, on sympathetic nerve activity in patients with essential hypertension. Blood Press 1994; 5 Suppl: 122-9.
22. Kannel WB, Kannel C, Paffenbarger RS Jr, Cupples LA. Heart rate and cardiovascular mortality: the Framingham Study. Am Heart J 1987; 6: 1489-94.
23. Ambrosioni E, Leonetti G, Pessina AC, Rappelli A, Trimarco B, Zanchetti A. Patterns of hypertension management in Italy: results of a pharmacoepidemiological survey on antihypertensive therapy. J Hypertens 2000; 18: 1691-9.
24. Crucitti A, Cecchi E, Gensini GF, et al. Use of antihypertensive drugs in the Italian hospitals. GIFA group. Gruppo Italiano di Farmacoepidemiologia nell'Anziano. Pharmacol Res 2000; 41: 249-53.